A randomized study assessing the effect of Opicapone 50 mg once daily on levodopa pharmacokinetics in different L-DOPA/carbidopa treatment-optimized regimens in patients with Parkinson's disease who demonstrate end-of-dose motor fluctuations
Latest Information Update: 28 Oct 2021
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Opicapone (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- 28 Oct 2021 New trial record
- 22 Sep 2021 Study design presented at the 25th International Congress of Parkinson's Disease and Movement Disorders